Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04797286
Other study ID # IRB00265164
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 20, 2021
Est. completion date September 2024

Study information

Verified date September 2023
Source Johns Hopkins University
Contact Stephen Mathai, MD
Phone 4106146311
Email smathai4@jhmi.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.


Description:

Data shows that sildenafil (SIL) is an effective therapy in SSc-PAH. SIL has been safely used in many patients with various vascular and cardiovascular diseases over the past three decades. Randomized controlled trial data for SIL shows improvement in 6MWD, hemodynamics, and even evidence of cardiac remodeling in PAH and SSc-PAH patients. Based upon these data, SIL may be an effective therapy in SSc-MEP. This study will help determine whether sildenafil could be a good treatment for patients with scleroderma that have mildly elevated pulmonary pressures.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date September 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Previous documentation of mean pulmonary artery pressure between 21 and 24 mm Hg with a pulmonary capillary wedge pressure (or left ventricular end-diastolic pressure) = 15 mm Hg within six months before study entry. - Diagnosis of SSc according to 2013 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) classification criteria. - Pulmonary function tests with forced expiratory volume in one second/forced vital capacity (FEV1/FVC) >50% AND either a) total lung capacity (TLC) or forced vital capacity (FVC) > 70% predicted or b) TLC or FVC between 60% and 70% predicted with no more than mild interstitial lung disease on computerized tomography scan of the chest on studies obtained within 6 months of enrollment. - Ventilation perfusion scan or computed tomography with intravenous contrast (CT angiogram) without evidence of chronic thromboembolism at anytime before study entry. - Ability to perform six minute walk testing without significant limitations in musculoskeletal function or coordination. - Informed consent. Exclusion Criteria: - World Health Organization (WHO) Class IV functional status. - Systolic blood pressure less than 90 mmHg at screening visit prior to enrollment. - Clinically significant untreated sleep apnea. - Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection fraction < 45% on most recent echocardiography (within 1 year). - Use of Pulmonary Arterial Hypertension (PAH) therapy (prostacyclin analogues, endothelin-1 receptor antagonists,phosphodiesterase-5 inhibitors, riociguat, selexipag) within the past 3 months. - Hospitalized or acutely ill. - Renal failure (creatinine above 2.0) at screening visit. - Enrollment in a clinical trial or concurrent use of another investigational drug (non FDA approved) or device therapy within 30 days of screening visit. - Age < 18. - Currently pregnant. - Current use of nitrates.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sildenafil
Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.
Other:
Placebo
Oral pill placebo.

Locations

Country Name City State
United States Johns Hopkins Baltimore Maryland
United States Louisiana State University New Orleans Louisiana

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University Louisiana State University Health Sciences Center in New Orleans

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in change in distance walked in 6 minute walk test (6MWT) at 4 months As assessed by change in 6 minute walk distance (6MWD) in feet (from baseline to 4 months) between the sildenafil group and the placebo group. Baseline and 4 months
Secondary Difference in change in distance walked in 6MWT at 12 months As assessed by change in 6 minute walk test distance in feet (from baseline to 12 months) between the sildenafil group and the placebo group. Baseline and 12 months
Secondary Difference in change in right ventricular function as assessed by cardiac MRI As assessed by change in right ventricular function (normal/abnormal) on cardiac MRI. Baseline and 4 months
Secondary Difference in change in right ventricular function as assessed by cardiac MRI As assessed by change in right ventricular function (normal/abnormal) on cardiac MRI. Baseline and 12 months
Secondary Difference in change in right ventricular function as assessed by invasive hemodynamics As assessed by change in right ventricular function (normal/abnormal) on invasive hemodynamics. Baseline and 4 months
Secondary Difference in change in right ventricular function as assessed by invasive hemodynamics As assessed by change in right ventricular function (normal/abnormal) on invasive hemodynamics. Baseline and 12 months
Secondary Difference in change in right ventricular function as assessed by echocardiography As assessed by change in right ventricular function (normal/abnormal) on echocardiography. Baseline and 4 months
Secondary Difference in change in right ventricular function as assessed by echocardiography As assessed by change in right ventricular function (normal/abnormal) on echocardiography. Baseline and 12 months
Secondary Difference in change in N-terminal pro b-type natriuretic peptide level As assessed by changes in plasma N-terminal pro b-type natriuretic peptide (NT-proBNP) level (pg/mL) between sildenafil and placebo groups at four months and twelve months. Baseline, 4 months and 12 months
Secondary Difference in change in health related quality of life as assessed by the 36-Item Short Form Health Survey (SF36) questionnaire As assessed by changes in SF36 questionnaire between sildenafil and placebo groups at four months and twelve months. The SF36 yields a set of scaled scores in 8 domains, with higher numbers representing a better quality of life. Each scale is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. In step 2, items in the same scale are averaged together to create the 8 scale scores. Items that are left blank (missing data) are not taken into account when calculating the scale scores. Hence, scale scores represent the average for all items in the scale that the respondent answered. Baseline, 4 months and 12 months
Secondary Difference in change in health related quality of life as assessed by the emPHasis-10 health-related quality of life questionnaire (emPHasis-10). As assessed by changes in emPHasis-10 questionnaire between sildenafil and placebo groups. The Emphasis 10 score consists of 10 questions scored in a semantic 6-point scale (from 0 to 5), for a total maximum score of 50 (the higher the score, the worse the quality of life). Baseline, 4 months and 12 months
Secondary Difference in safety profile as assessed by frequency of adverse events As assessed by frequency of adverse events between sildenafil and placebo groups. Ongoing until study closes, up to 4 years
Secondary Difference in safety profile as assessed by severity of adverse events As assessed by severity of adverse events between sildenafil and placebo groups. Ongoing until study closes, up to 4 years
See also
  Status Clinical Trial Phase
Completed NCT02798055 - Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
Completed NCT01959815 - Novel Screening Strategies for Scleroderma PAH
Completed NCT03274076 - Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Phase 1/Phase 2
Completed NCT02915835 - Riociguat in Scleroderma Associated Digital Ulcers Phase 2
Active, not recruiting NCT01895244 - Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis Phase 2
Completed NCT00883129 - Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Phase 2
Completed NCT00930683 - A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma Phase 1
Completed NCT00074568 - Scleroderma Registry
Completed NCT03222492 - Brentuximab Vedotin for Systemic Sclerosis Phase 1/Phase 2
Completed NCT03207997 - MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients N/A
Recruiting NCT04464434 - Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis Phase 4
Recruiting NCT04246528 - SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF) N/A
Completed NCT05080738 - Upper Extremity Home Exercises in Patients With Scleroderma N/A
Recruiting NCT03726398 - CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH Phase 2/Phase 3
Recruiting NCT05085444 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma Early Phase 1
Completed NCT02062125 - Calcinosis in a Single-Center Scleroderma Population
Completed NCT04588714 - Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention N/A
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT02835196 - Optical Elastography of Systemic Sclerosis Skin
Completed NCT02896205 - Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease Phase 3